Donor erythrocytosis induced by sorafenib treatment after allogeneic hematopoietic SCT in a patient with acute myeloid leukemia

Bone Marrow Transplant. 2012 Jun;47(6):872-3. doi: 10.1038/bmt.2011.183. Epub 2011 Sep 19.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects*
  • Benzenesulfonates / administration & dosage
  • Benzenesulfonates / adverse effects*
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Leukemia, Myeloid, Acute
  • Male
  • Niacinamide / analogs & derivatives
  • Phenylurea Compounds
  • Polycythemia / chemically induced*
  • Polycythemia / drug therapy
  • Pyridines / administration & dosage
  • Pyridines / adverse effects*
  • Sorafenib
  • Transplantation, Homologous
  • Unrelated Donors*

Substances

  • Antineoplastic Agents
  • Benzenesulfonates
  • Phenylurea Compounds
  • Pyridines
  • Niacinamide
  • Sorafenib